Check out the companies making headlines in midday trading. Bristol Myers Squibb — The drug maker jumped more than 3% after the Food and Drug Administration approved a highly anticipated schizophrenia drug , the first novel type of treatment for the chronic mental disorder in more than seven decades. Bristol Myers Squibb expects the twice-daily pill, which will be sold under the brand name Cobenfy, to be available in late October. Novo Nordisk — U.S.-listed shares of the Danish drugmaker slid 2.
" Cassava Sciences — The biotech company fell 11% after agreeing to pay $40 million to settle a case with the Securities and Exchange Commission. The charges were over "misleading statements" made in 2020 related to a clinical trial for a purported Alzheimer's disease treatment. Wynn Resorts — The stock rose about 6% thanks to an upgrade to overweight from equal weight at Morgan Stanley.